

# Dr. Majid Khamis Al Salmani

Assistant Professor Biomedical Sciences Natural and Medical Sciences Research Center University of Nizwa, Sultanate of Oman

Extension: 762

eMail: majid.al.salmani@unizwa.edu.om

Office Location: Building 25B.

Time at UoN: Since 2018

I am interested in investigating the mechanisms of ion transport across the plasma membranes of living cells. We focus on understanding the molecular defects that cause diseases such as cystic fibrosis. We employ electrophysiological, imaging and biochemical techniques to better understand the root cause of theses conditions.

#### **Academic Qualifications**

Ph.D., University of Bristol, 2017

B.Sc. (Honours), The University of Glasgow, 2010

#### **Teaching Activities**

Human Physiology, BIOL300

Human Physiology Laboratory, BIOL300L

Undergraduate lab projects

#### **Research Activities**

- Research Interests

Ion channels

Channelopathies

**Cystic Fibrosis** 

Cystic fibrosis transmembrane conductance regulator (CFTR)

Long QT syndrome

Human ether-a-go-go related gene (hERG) K+ channels

## - Conference Attendance

New Roles for Ion Channels and Transporters in Health and Disease, UK (virtual), 02/09/2021

Electrophysiology & Imaging - a virtual Plymouth Workshop, Plymouth, UK (virtual), 01/09/2021

Physiology 2021 meeting, UK (Virtual), 12/07/2021

Young Physiologist meeting, Germany (Virtual), 01/06/2021

The First Biomedical Sciences Conference in Oman, Sultan Qaboos University, 26/02/2020

16th European Cystic Fibrosis Society Basic Science Conference, Dubrovnik (Croatia),

27/03/2019

EuroPhysiology2018, London (UK), 13/08/2018

#### - Publications

#### Article:

1. 2022 Multiple mechanisms underlie reduced potassium conductance in the

p.T1019PfsX38 variant of hERG, Al Salmani MK, Tavakoli R, Zaman W, Al Harrasi A. Physiol Rep. 2022 Jul;10(14):e15341. doi: 10.14814/phy2.15341. PMID: 35854468; PMCID: PMC9296870.

2. 2021 <u>Molecular epidemiology of COVID-19 in Oman: A molecular and surveillance study</u> for the early transmission of COVID-19 in the country, Al-Mahruqi S, Al-Wahaibi A, Khan AL, Al-Jardani A, Asaf S, Alkindi H, Al-Kharusi S, Al-Rawahi AN, Al-Rawahi A, Al-Salmani M, Al-Shukri I, Al-Busaidi A, Al-Abri SS, Al-Harrasi A. Int J Infect Dis. 2021 Jan 13;104:139-149. doi: 10.1016/j.ijid.2020.12.049. Epub ahead of print. PMID: 33359061; PMCID: PMC7834852.

3. 2015 <u>The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for</u> <u>Monitoring Patient`s Symptoms</u>, Oman Medical Journal 30, 17-25.  4. 2015 <u>A Specific Haplotype Framework Surrounds the Omani Cystic Fibrosis</u> <u>Transmembrane Conductance Regulator (CFTR) Mutation S549R</u>, Jordan Journal of Biological Sciences 8, 37 - 43.

5. 2014 <u>Defining a mutational panel and predicting the prevalence of cystic fibrosis in</u> <u>Oman.</u>, Sultan Qaboos Univ Med J. 14(3):e323-9.

### **Book Section:**

1. 2020 <u>Molecular Physiology and Pharmacology of the Cystic Fibrosis Transmembrane</u> <u>Conductance Regulator</u>, Al Salmani M.K., Sondo E., Balut C., Sheppard D.N., Singh A.K., Pedemonte N. (2020) Molecular Physiology and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator. In: Hamilton K.L., Devor D.C. (eds) Studies of Epithelial Transporters and Ion Channels. Physiology in Health and Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-55454-5\_16

2. 2014 <u>Chapter 1: Features of the CFTR CI- channel: relating structure to function</u>, In
``Mutation-specific therapies in cystic fibrosis – Current status and prospects``; UNI-MED
SCIENCE. Editor: Burkhard Tümmler

## **Community Services**

06/09/2021: Members of Jury, Falling Walls Lab 2021

30/05/2021: Animal ethics committee

08/11/2018: Biological ethics committee

## Membership in Professional Bodies

2021-Present: The Physiological Society